Clinical Trials: Post-Approval Commitments

What Are Post-Approval Commitments and When Are They Needed?

Posted on digi By digi

Gaining marketing authorization is a critical milestone in the lifecycle of a drug or biologic. However, it does not mark the end of regulatory scrutiny. Post-approval commitments (PACs)—which include post-marketing requirements (PMRs) and post-marketing commitments (PMCs)—are essential mechanisms used by health authorities to continue assessing the safety, efficacy, and quality of approved products.

Click to read the full article.

Post-Approval Commitments, Regulatory Submissions and Approvals

Post‑Marketing Safety Study Obligations Explained

Posted on digi By digi

Approval of a drug or biologic does not eliminate the need for ongoing safety monitoring. Post‑marketing safety studies are designed to detect rare adverse events, assess long-term safety, and evaluate real‑world effectiveness. Regulatory authorities such as the FDA, EMA, PMDA, and Health Canada often require these studies as commitments or conditions of approval to protect public health.

Click to read the full article.

Post-Approval Commitments, Regulatory Submissions and Approvals

Annual Report Submissions for Post-Approval Studies

Posted on digi By digi

After approval, many products are subject to post‑approval study obligations—such as Post-Marketing Requirements (PMRs) in the U.S., or Post-Authorization Safety Studies (PASS) in Europe. Sponsors must submit **annual reports** to health authorities to update on the status, progress, and findings of these studies. These reports maintain compliance, demonstrate continued commitment to safety, and frequently influence future regulatory decisions.

Click to read the full article.

Post-Approval Commitments, Regulatory Submissions and Approvals

Maintaining Labeling Compliance After Approval

Posted on digi By digi

Product labeling is a living document that guides clinical use, informs patients, and serves as a legal reference for healthcare professionals. Following regulatory approval, labeling must be continually managed to reflect new safety information, updated usage guidance, pediatric expansions, and risk mitigation strategies. Failure to keep labeling compliant can lead to safety issues, regulatory citations, or loss of approval.

Click to read the full article.

Post-Approval Commitments, Regulatory Submissions and Approvals

Real‑World Evidence as Part of Post‑Approval Commitments

Posted on digi By digi

After a drug or biologic gains regulatory approval, its journey is far from over. Regulators often impose post‑approval commitments—studies designed to confirm long-term safety, effectiveness, and risk mitigation strategies in the real-world population. While randomized controlled trials (RCTs) have long been the gold standard, they can be expensive, time-consuming, and less reflective of real-world conditions.

Click to read the full article.

Post-Approval Commitments, Regulatory Submissions and Approvals

Communication of Post‑Approval Changes to Stakeholders

Posted on digi By digi

After a product has been approved and launched, regulatory expectations do not end—the communication of post‑approval changes becomes crucial. These modifications may include updates to labeling, safety monitoring measures, manufacturing, packaging, or indications. Informing stakeholders such as health authorities, healthcare providers, patients, field teams, and internal departments is essential for ensuring safe use, maintaining regulatory compliance, and preserving trust.

Click to read the full article.

Post-Approval Commitments, Regulatory Submissions and Approvals

From IND Clinical Hold to Approval: Strategies and Timeline Management

Posted on digi By digi

A clinical hold issued by the FDA on an Investigational New Drug (IND) application stops clinical research activities outright until the agency’s concerns are adequately addressed. Holds may be triggered for safety reasons, unclear data, incomplete chemistry documentation, or gaps in nonclinical toxicology. An IND hold halts trial initiation and significantly extends development timelines—delays that impact both strategy and budget.

Click to read the full article.

Post-Approval Commitments, Regulatory Submissions and Approvals

Regulatory Sandbox and Pilot Programs: Opportunities for Innovation and Expedited Engagement

Posted on digi By digi

Regulatory sandboxes and associated pilot programs are collaborative initiatives launched by health authorities like the FDA to foster innovation in drug development and evidence generation. These frameworks allow sponsors to test novel approaches—such as use of real-world data, digital health technologies, or advanced manufacturing—within a controlled, regulatory-guided setting.

Click to read the full article.

Post-Approval Commitments, Regulatory Submissions and Approvals